Halyard Health, Inc. (HYH) Upgraded by ValuEngine to Buy

ValuEngine upgraded shares of Halyard Health, Inc. (NYSE:HYH) from a hold rating to a buy rating in a report released on Saturday, November 4th.

A number of other analysts have also issued reports on HYH. Zacks Investment Research lowered Halyard Health from a buy rating to a sell rating in a research note on Wednesday, October 4th. BidaskClub raised Halyard Health from a hold rating to a buy rating in a research note on Saturday, August 19th. TheStreet lowered Halyard Health from a b- rating to a c+ rating in a research note on Monday, October 30th. KeyCorp reissued a hold rating on shares of Halyard Health in a research note on Tuesday, October 17th. Finally, Stifel Nicolaus reissued a buy rating and issued a $52.00 price target on shares of Halyard Health in a research note on Friday, November 3rd. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Halyard Health currently has a consensus rating of Buy and a consensus price target of $44.00.

Shares of Halyard Health (NYSE HYH) remained flat at $$46.67 during mid-day trading on Friday. 218,800 shares of the company’s stock traded hands, compared to its average volume of 349,598. Halyard Health has a 12-month low of $35.24 and a 12-month high of $50.99. The firm has a market cap of $2,185.86, a PE ratio of 22.33, a PEG ratio of 2.52 and a beta of 1.69. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.13 and a quick ratio of 1.19.

Halyard Health (NYSE:HYH) last announced its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.13. Halyard Health had a return on equity of 8.65% and a net margin of 3.52%. The business had revenue of $401.40 million during the quarter, compared to analysts’ expectations of $394.54 million. During the same quarter last year, the business posted $0.48 earnings per share. The business’s revenue for the quarter was up 1.0% on a year-over-year basis. equities analysts expect that Halyard Health will post 2.08 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first published by BBNS and is owned by of BBNS. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://baseballnewssource.com/markets/halyard-health-inc-hyh-rating-increased-to-buy-at-valuengine/1758435.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Riverhead Capital Management LLC lifted its stake in shares of Halyard Health by 88.1% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,197 shares of the medical instruments supplier’s stock valued at $126,000 after purchasing an additional 1,497 shares in the last quarter. LS Investment Advisors LLC raised its holdings in shares of Halyard Health by 16.1% during the 2nd quarter. LS Investment Advisors LLC now owns 4,017 shares of the medical instruments supplier’s stock valued at $158,000 after buying an additional 556 shares during the period. Jarislowsky Fraser Ltd purchased a new stake in shares of Halyard Health during the 3rd quarter valued at about $200,000. Quotient Investors LLC purchased a new stake in shares of Halyard Health during the 3rd quarter valued at about $203,000. Finally, Jane Street Group LLC purchased a new stake in shares of Halyard Health during the 3rd quarter valued at about $211,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.